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Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), with focal T lymphocytic infiltration 
and damage of myelin and axons. The underlying mechanism of pathogenesis remains unclear and there are currently no effec-
tive treatments. The development of neural stem cell (NSC) transplantation provides a promising strategy to treat neurodegen-
erative disease. However, the limited availability of NSCs prevents their application in neural disease therapy. In this study, we 
generated NSCs from induced pluripotent stem cells (iPSCs) and transplanted these cells into mice with experimental autoim-
mune encephalomyelitis (EAE), a model of MS. The results showed that transplantation of iPSC-derived NSCs dramatically 
reduced T cell infiltration and ameliorated white matter damage in the treated EAE mice. Correspondingly, the disease symp-
tom score was greatly decreased, and motor ability was dramatically rescued in the iPSC-NSC-treated EAE mice, indicating 
the effectiveness of using iPSC-NSCs to treat MS. Our study provides pre-clinical evidence to support the feasibility of treat-
ing MS by transplantation of iPSC-derived NSCs. 
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Multiple sclerosis (MS) is a neurodegenerative disease, 
which leads to axon loss and myelin damage in the central 
neural system (CNS) of patients (Compston and Coles, 
2008). Currently, the exact pathological mechanism of MS 
is still unclear. One hypothesis suggests that MS is an au-
toimmune disease. Lymphocytic cells, recruited by the au-
toimmune response occurring in the CNS, disrupt the 
blood-brain barrier and infiltrate the CNS. Immune cells 
that reach the CNS may survive for a long time, inducing 
demyelination and irreversible axon loss (Arima et al., 
2013; Viglietta et al., 2004). Currently, clinical MS therapies 
mainly rely on immunomodulatory drugs such as natali-
zumab, mitoxantrone, and azathioprine (Constantinescu et al., 
2011; Jelinek et al., 2015; Kleinschmidt-DeMasters and 
Tyler K, 2005). These drug treatments can alleviate disease 
symptoms and reduce relapse frequency to some extent. 
However, drug treatment cannot rescue the neuronal dam-
age within the neural lesions. Remyelination and neural cell 
regeneration are still major hurdles for MS treatments.  
Recent progress and remarkable advancement in stem 
cell research has led to an exciting prospect of regenerative 
medicine and provided new strategies to treat neurodegen-
erative disease (Huang and Fu, 2014). Human embryonic 
stem cell (ESC)-derived NSCs transplanted into the Parkin-
son’s rodent model have been reported to successfully gen- 
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erate DA neurons in the host and ameliorate the disease 
(Ben-Hur et al., 2004; Kim et al., 2002; Redmond et al., 
2007). Detailed tracing experiments showed that human 
NSCs injected into a Huntington’s mouse model migrate 
into the striatal lesion and promote long-term recovery of 
neural function (Lee et al., 2005). Interestingly, intrahippo-
campal injection of human NSCs promoted cognitive func-
tion in an Alzheimer’s mouse model, indicating that trans-
planted NSCs can functionally integrate into the host (Ager 
et al., 2015). Furthermore, stem cell transplantation has also 
provided new strategies to treat neural autoimmune disease. 
Early reports showed that transplantation of adult neural 
progenitor cells promoted neural function recovery in the 
EAE mouse model of multiple sclerosis. A recent study 
suggested that transplantation of bone marrow derived 
mesenchymal stem cells (MSCs) alleviated the progression 
of MS-like symptoms in EAE mice (Harris et al., 2012). 
These experiments support the development of neural stem 
cells to treat diseases that involve neural degeneration or 
damage. However, the limited availability of neural stem 
cells restricts the large-scale expansion of neural stem cell 
therapy (Kim et al., 2012; Pluchino and Martino, 2008; 
Pluchino et al., 2003).  
Induced pluripotent stem cells (iPSCs) exhibit transcrip-
tional and epigenetic characteristics that are highly similar 
to those of ESCs (Takahashi and Yamanaka, 2006). Similar 
to ESCs, iPSCs can undergo self-renewal and maintain plu-
ripotency to differentiate into any cell type. Thus iPSCs can 
potentially provide unlimited autologous cells for therapy, 
and hold great promise for regenerative medicine. Safety 
and efficacy are the most important questions for clinical 
development of iPSCs. The therapeutic potential of iPSCs 
has been extensively assessed by transplantation of 
iPSC-derived specific cells into different animal disease 
models (Liu et al., 2014; Lu and Zhao, 2013). However, at 
the same time, it has been reported that the residual undif-
ferentiated cells inside the iPSC-differentiated specific lin-
eage might cause tumor formation after transplantation (Liu 
et al., 2014; Lu and Zhao, 2013). Furthermore, it has been 
shown that certain cells derived from iPSCs can elicit anti-
gen-specific immune rejection responses after transplanta-
tion into the autologous recipients (Zhao et al., 2011, 2015). 
Thus it is necessary to extensively examine the safety and 
efficacy of iPSC-NSCs for therapy. 
Mice with experimental autoimmune encephalomyelitis 
(EAE) are widely used to model MS. EAE has many simi-
larities to MS, such as demyelination and axon loss 
(Constantinescu et al., 2011). In this study, we differentiated 
C57BL/6 mouse iPSCs into NSCs in vitro and transplanted 
these cells into EAE mice to evaluate their therapeutic ef-
fects. We found that transplanted NSCs derived from iPSCs 
in vitro were integrated into the nervous system and the 
infiltration of T cells into the CNS was greatly reduced. 
Correspondingly, NSC transplantation promoted remye-
lination and improved the recovery of motor function in the 
EAE mice.  
RESULTS 
Induction of the EAE model  
To investigate the therapeutic efficacy of iPSC-NSC trans-
plantation, we first established EAE in mice as a model of 
MS. EAE was induced by injecting mice with myelin oli-
godendrocyte glycoprotein peptide 35–55 (MOG35–55) 
emulsified in complete Freund’s adjuvant (CFA). The level 
of disease symptoms was assessed with a standard score 
ranging from 0 to 5 (Figure 1A). Mice that scored 3 (severe 
hindlimb weakness) were sacrificed and the spinal cords 
were stained with hematoxylin-eosin (HE) (Figure 1A). 
Compared to normal control mice, the EAE mice had seri-
ous tissue necrosis and dispersed cell infiltration at the edge 
of the white matter, suggesting that the CNS was destroyed 
in the diseased mice (Figure 1B). Anti-MBP staining 
showed marked demyelination at the outer edge of the white 
matter in EAE mice but not normal controls (Figure 1B and 
C). Furthermore, staining the sections with anti-CD3, an-
ti-CD4 and anti-CD8 antibodies revealed extensive infiltra-
tion of T cells into the spinal cords of the EAE mice but not 
the normal controls (Figure 1D).  
The Treadscan system was used to collect, analyze, and 
quantify gait data from the EAE mice and normal mice 
based on a video recording of mice walking in a relaxed 
state. The disability of EAE mice was characterized by four 
different indexes: swing time of rear feet, stride time of rear 
feet, stride length and average instant running speed. We 
found that the swing time and stride time of the rear feet 
were much longer in EAE mice than normal mice. The 
stride length and average instant running speed of rear foot 
were lower than those of normal mice (Figure 1E). Fur-
thermore, open-field assays showed that the total running 
distance, the time spent in the central area and the number 
of times the animals entered the central area was lower for 
EAE mice than for normal mice, further confirming the lim-
ited mobility of EAE mice (Figure 1F). 
Differentiation of NSCs from iPSCs in vitro 
We used a modified monolayer neural differentiation  
protocol to differentiate iPSCs into NSCs (Figure 2A) 
(Okabe et al., 1996; Ying et al., 2003). To get more pure 
neural stem cells for transplantation, the cells were dissoci-
ated by trypsin on day 12 of differentiation and plated into a 
new plate for continue culturing. The differentiated cells 
were aggregated and propagated as neural spheres (Figure 
2A and B). Further characterization showed that these cells 
were positive for Nestin and Sox2, like primary neural stem 
cells. Most importantly, these iPSC-derived cells can dif-
ferentiate into Tuj1-positive neurons, indicating their neural 
differentiation potential (Figure 2D).  
Transplantation of iPSC-NSCs effectively improves the 
functional recovery of EAE mice 
To investigate whether the transplanted NSCs can integrate 
into the host and functionally repair the damaged neural 
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Figure 1  Characterization of EAE mice. A, Mice immunized with MOG35–55 show an increased score of disease symptoms. B, Images of H&E-stained 
sections of spinal cord from normal and EAE mice. Scale bars, 200 μm (Top), 100 μm (Bottom). C, EAE mice show demyelination and axon loss. Spinal 
cord sections from EAE and normal mice were stained with anti-MBP antibody and DAPI, and analyzed by fluorescence microscopy. Blue, DAPI. Green, 
MBP. Scale bars, 200 μm. D, The spinal cords of EAE mice are extensively infiltrated with T cells. T cells were identified with anti-CD3, anti-CD4 and 
anti-CD8 antibodies. Sections from the spleen were used as a positive control. Scale bars, 100 μm. E, EAE mice show compromised mobility. The instant 
running speed, stride lengths, stride time and swing time of EAE mice were determined by GaitScan. Data shown as mean±standard deviation (SD), n=3;   
*, P<0.05. **, P<0.01, Student’s t-test. F, EAE mice have defective spontaneous movement compared to normal mice. An open-field experiment was used to 
determine the average speed, the total running distance and the number of entries into the central area.  
 
Figure 2  Generation and characterization of neural stem cells derived from B6 iPSCs. A, Scheme of neural stem cell differentiation from iPSCs in vitro. B, 
Morphology of neural progenitor cells at distinct stages of differentiation. Scale bars, 200 μm. C, Neural stem cells derived from B6 iPSCs (iPSC-NSCs) 
express Nestin and Sox2. Red, Nestin. Green, Sox2. Blue, DAPI. Scale bars, 50 μm. D, iPSC-NSCs can differentiate into Tuj1-positive neurons. Green, Tuj1. 
Blue, DAPI. Scale bars, 100 μm. 
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tissues, the iPSC-NSCs were labeled with a lentivirus vector 
expressing mCherry (pCDH-mCherry) to trace their loca-
tion after transplantation (Figure 3A). The mCherry-labeled 
iPSC-NSCs were transplanted into the lateral ventricle of 
EAE mice. The brains of the EAE mice were extensively 
examined at different days after administration of iPSC- 
NSCs, and mCherry-RFP-positive cells were routinely de-
tected in the dentate gyrus within one month of transplanta-
tion (Figure 3B). Most importantly, mCherry-RFP was de-
tected to co-localize with the neuron marker Tju1 in the 
lesion areas, indicating the integration and differentiation of 
iPSC-NSC-derived neurons into the damaged tissues (Fig-
ure 3B). 
The structural and functional recovery of the EAE mice 
was monitored for two months after iPSC-NSC injection. 
Using anti-MBP antibody staining, we found that trans-
plantation of iPSC-NSCs but not allogeneic NSCs leads to 
remyelination in the marginal zone of the white matter 
(Figure 3C). Correspondingly, iPSC-NSCs but not alloge-
neic NSCs greatly decreased the EAE score, indicating the 
functional recovery of the EAE mice by iPSC-NSC treat-
ment (Figure 3D). Furthermore, we performed Treadscan 
analysis to investigate motor function recovery, and found 
that transplantation of iPSC-NSCs but not allogeneic NSCs 
dramatically improved the motor ability of EAE mice (Fig-
ure 3E and F). Together, these data suggest that transplanta-
tion of iPSC-NSCs can effectively promote remyelination 
of the damaged spinal cords, alleviate EAE disease symp-
toms, and improve motor function. 
Immunogenicity analysis of iPSC-NSCs  
It has been shown that certain cell types derived from iP-
SCs, like smooth muscle cells and endothelium cells, can be 
rejected after transplantation into autologous recipients 
 
 
Figure 3  Transplantation of iPSC-NSCs improves the motor function of EAE mice. A, The iPSC-NSCs are marked with pCDH-mCherry for cell fate 
tracing after transplantation. Green, Nestin and Sox2. Red, mCherry. Blue, DAPI. Scale bars, 50 μm. B, The transplanted iPSC-NSCs differentiate into neu-
rons and integrate into the lesions in EAE mice. Red, mCherry. Green, Tju1. Blue, DAPI. Scale bars, 100 μm. C, EAE mice with transplanted iPSC-NSCs 
show remyelination in the lesion area. Red, MBP. Blue, DAPI. Scale bars, 200 μm. D, EAE symptoms are improved by iPSC-NSC transplantation. NSCs 
isolated from syngeneic C57BL/6 mice and allogeneic ICR mice were transplanted into the EAE mice, and used as positive and negative controls respec-
tively. E, The mobility of EAE mice is recovered by iPSC-NSC transplantation. Stride length, instant speed, stride time and swing time were determined by 
GaitScan analysis. NSCs isolated from syngeneic C57BL/6 mice and allogeneic ICR mice were transplanted into EAE mice, and used as positive and nega-
tive controls respectively. F, Open-field experiment showing recovery of mobility in EAE mice treated with iPSC-NSC transplantation. Entries into the 
central area, total distance and average speed were recorded and analyzed by GaitScan software. NSCs isolated from syngeneic C57BL/6 mice and allogene-
ic ICR mice were transplanted into EAE mice, and used as positive and negative controls respectively. 
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(Araki et al., 2013; de Almeida et al., 2014). To investigate 
whether NSCs derived from iPSCs can elicit immune rejec-
tion responses and thus affect their clinical applications, T 
cell stimulation assays were performed. Splenic T cells 
were isolated from B6 mice that received NSC transplanta-
tion, labeled with carboxy fluorescein succinimidyl ester 
(CFSE), co-cultured with syngeneic iPSC-NSCs or alloge-
neic NSCs, and then analyzed with flow cytometry. T cells 
co-cultured with NSCs proliferated extensively, while T 
cells stimulated with iPSC-NSCs were not induced to pro-
liferate, indicating that iPSC-NSCs have limited immuno-
genicity (Figure 4A and B). 
To investigate whether iPSC-NSC transplantation allevi-
ates the autoimmune disease characteristics of EAE, we 
performed immune staining of spinal cords from EAE mice 
treated with ICR-NSCs or iPSC-NSCs. Transplantation of 
iPSC-NSCs, but not ICR-NSCs, greatly reduced the infiltra-
tion of T cells into the spinal cords of EAE mice (Figure 
4C). This indicates that iPSC-NSC transplantation not only 
repaired the damaged neurons but also alleviated the auto-
immune rejection responses.  
DISCUSSION 
Recent reports showed that both MSC and hematopoietic 
stem cells (HSC) transplantation had impressive therapeutic 
effects on MS when compared to traditional drug treatments 
(Fisher-Shoval et al., 2012; Lajimi et al., 2012). Mechanis-
tic studies indicated that the transplanted human MSCs sta-
bilized the symptoms in progressive MS and prevented se-
vere exacerbation, whereas the HSCs played a role in im-
mune modulation, which could reduce relapse, relieve 
symptoms and slow the progression of disability after trans-
plantation (Fassas et al., 1997). However, transplantation of 
HSCs and/or MSCs could not repair damaged neural cells 
and myelin, and thus could stabilize the progression of dis-
ease but could not cure it. NSCs can be maintained in vitro 
and differentiated into distinct types of neural cells, making 
them an ideal resource for therapy. A number of studies 
have demonstrated that neural progenitor cell transplanta-
tion significantly promotes the recovery of damaged neu-
rons in both mouse models (Bai et al., 2013; Einstein et al., 
2003; Kim et al., 2012; Wu et al., 2013) and primate models 
(Pluchino et al., 2009). However, a lack of neural progenitor 
sources and immune rejection are the two bottlenecks re-
stricting the development of this new MS treatment strate-
gy. NSCs derived from patients’ own iPSCs can potentially 
resolve these issues (Cundiff and Anderson, 2011; 
Durnaoglu et al., 2011; Israel et al., 2012). In this study, we 
generated mouse iPSCs, differentiated these cells into NSCs 
in vitro, transplanted them into EAE mice, and evaluated 
their therapeutic efficacy. The transplanted NSCs can dif-
ferentiate into neurons and integrate into damaged tissues in 
the recipient. Correspondingly, the iPSC-NSC treatment 
greatly alleviated the disease phenotype and improved the 
mobility of EAE mice.  
MS is an autoimmune disease in which the underlying 
pathological mechanism remains unclear. Transplantation of 
 
 
Figure 4  iPSC-NSC transplantation reduces T cell infiltration. A, T cells are activated by allogeneic but not syngeneic NSCs. CD4+ and CD8+ T cells were 
stained with CFSE and co-cultured with allogeneic or syngeneic NSCs. The proliferation of T cells was determined by a flow cytometry. B, In vitro differen-
tiated iPSC-NSCs do not induce an immune rejection response. CD4+ and CD8+ T cells were isolated from C57BL/6 mice receiving PBS, allogeneic ICR 
NSCs, syngeneic C57BL/6 NSCs or iPSC-NSCs, and were co-cultured with the grafts. C, Transplantation of iPSC-NSCs reduces infiltration of T cells inside 
the spinal cord of EAE mice. T cells were identified by anti-CD3, anti-CD4 and anti-CD8 antibodies. Sections from the spleen were used as a positive con-
trol. Scale bars, 100 μm. 
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HSCs/MSCs cannot repair damaged neurons, but dramati-
cally alleviates the immune attack, preventing disease dete-
rioration. Surprisingly, the iPSC-NSC transplantation in our 
study not only repaired the damaged tissues, but also dra-
matically decreased T cell infiltration in the treated EAE 
mice. The mechanisms underlying the reduction of inflam-
mation in the CNS are unclear. One possibility is that the 
tissues repaired by iPSC-NSC transplantation lose the abil-
ity to further recruit new lymphocytic cells.  
In 2011, we used a teratoma formation assay to show that 
mouse iPSC derivatives can be immunogenic. However, we 
did not identify at that time which kinds of cell/tissue inside 
the teratoma elicited the immune rejection response  
(Zhao et al., 2011). One follow-up study has shown that 
cardiomyocytes but not skin cells derived from mouse iP-
SCs can induce T cell infiltration after transplantation 
(Araki et al., 2013). In support of that view, a recent study 
has shown that autologous endothelial cells derived from 
iPSCs can elicit an immune response that resembles the one 
against self. Interestingly, these iPSC-derived autologous 
endothelial cells prompt a tolerance response characterized 
by increased expression of IL-10 (de Almeida et al., 2014). 
In this study, we did not observe an immune rejection re-
sponse upon iPSC-NSC transplantation. Together, these 
studies suggest that certain cells derived from iPSCs are 
immunogenic, while others are not (Cao et al., 2014;  
Zhao et al., 2015).  
The successful repair of damaged neural cells and mye-
lin, alleviation of T cell infiltration, and improvement of 
motor ability upon iPSC-NSC administration in EAE mice 
indicate that iPSC-NSCs can integrate into the recipient and 
cure the disease. These studies support the feasibility of 
treating MS using autologous NSCs derived from iPSCs. 
Further experiments using human or non-human primate 
iPSC-derived NSCs to evaluate the therapeutic efficacy will 
significantly speed up the clinical development of iPSC- 
derived NSCs. 
MATERIALS AND METHODS  
Induction of EAE and administration of NSCs 
All mice used were purchased from Vital River Inc China. 
Seven-week-old male C57BL/6 mice with an average body 
weight ranging from 17–19 g were selected and immunized 
subcutaneously with emulsion contained 200 μg MOG35–55. 
The MOG35–55 was diluted in 100 μL phosphate buffer sa-
line (PBS), 100 μL complete Freund’s adjuvant (CFA, Sig-
ma, USA), and 10 mg mL1 Mycobacterium tuberculosis 
(H37Ra) (TB, Difco, USA). The mice were then injected 
with 1 μg μL1 pertussis toxin (PT, Sigma) twice within  
48 h. All mice were monitored daily for clinical signs of 
EAE and evaluated by a standard disease score ranging 
from 0 to 5:0, no abnormality. 1, limp tail. 2, mild hindlimb 
weakness. 3, severe hindlimb weakness. 4, complete 
hindlimb paralysis. 5, death. When the mice showed severe 
hindlimb weakness (usually 18 days after disease induc-
tion), they were divided into four groups and treated with 
PBS, syngeneic C57BL/6 NSCs, allogeneic ICR NSCs and 
iPSC-NSCs. Each group contains 10 mice for transplanta-
tion. All NSCs were delivered into mice by intraventricular 
injection. Briefly, mice were anesthetized and fixed on the 
platform of the stereotaxic apparatus. Each mouse brain was 
injected with 2×105 cells in 10 μL PBS. Disease symptoms 
were usually monitored for three months.  
In vitro differentiation from iPS cells to neural stem cells 
Neural stem cell differentiation from iPSCs was performed 
by modifying a published protocol (Okabe et al., 1996; 
Ying et al., 2003). Briefly, undifferentiated iPS cells were 
seeded on a 0.1% gelatin-coated plate with a density of 
1×104 cm2 in ES medium without LIF for five days. At day 
6, ES culture medium (knockout Dulbecco’s modified ea-
gle’s medium with 15% fetal bovine serum, 2 mmol L1 
glutamine, 1 mmol L1 sodium pyruvate, 0.1 mmol L1 non- 
essential amino acids, 100 μg mL1 streptomycin, 100 U mL1 
penicillin, 0.055 mmol L1 -mercaptoethanol, and 1,000  
U mL1 leukemia inhibitory factor) was changed to a modified 
NSC differentiation N2B27 medium. The N2B27 medium is 
a 1:1 mixture of DMEM/F12 (Gibco, USA) supplemented 
with modified N2 (25 µg mL1 insulin, 100 µg mL1 trans-
ferrin, 6 ng mL1 progesterone, 16 µg mL1 putrescine,  
30 nmol L1 sodium selenite and 50 µg mL1 bovine serum 
albumin fraction V) (Gibco) and Neuron basal medium 
supplemented with B27 (both from Gibco). The NSC dif-
ferentiation medium was replaced every two days. After 
seven days culturing, cells were dissociated with 0.05% 
trypsin/0.04% EDTA and transferred to a non-adherent 
plate. These cells were then cultured in NSC medium which 
was Neuron basal medium supplemented with N-2 supple-
ment (1:100), B-27 supplement (1:50), 10 µg mL1 bFGF 
and EGF. 
T cell activation assay 
CD4+ and CD8+ T cells were isolated from the mouse 
spleens. Spleens were pulverized and fractionated on a Per-
coll gradient. The isolated cells were washed twice with 
PBS, then CD4+ and CD8+ T cells were sorted using a 
magnetic purification kit (Miltenyi, Germany). The CD4+ 
and CD8+ cells (responder, R) were labeled with CFSE 
(Invitrogen, USA) and co-cultured with the corresponding 
NSCs (stimulator, S) for 72 h. Flow cytometric analysis was 
performed to determine the activation of T cells.  
Immunohistochemistry 
The tissue samples were fixed in 4% paraformalin overnight 
at 4C and immersed in 30% sucrose solution overnight for 
dehydration. Tissues were then embedded in OCT for sec-
tioning (10 μm). The sections were stained by anti-CD3, 
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anti-CD4 and anti-CD8 antibodies (eBioscience, USA). 
Staining with primary antibodies was performed with an 
immunohistochemistry kit (ZSGB-BIO, Beijing). All imag-
es were captured using a Leica SCN400 scanner (Leica, 
Japan). For cell samples, cells cultured on cover slips were 
fixed in 4% paraformalin for 10 minutes, and rinsed in 0.1% 
Triton for 1 h. Then slips were blocked by 0.2% BSA for  
1 h and incubated with primary antibodies against Nestin 
(1:300, Millipore, USA), Sox2 (1:500, Abcam, UK), or 
MBP (1:400, Santa Cruz, USA) overnight at 4C. Cells 
were washed twice with PBS and incubated with AlexaFluor- 
conjugated secondary antibodies (1:2000, Invitrogen) for  
1 h. 4′,6-diamidino-2-phenylindole (DAPI) was added 30 min 
before observation (1:500, Invitrogen). All images were 
captured using a Zeiss LSM 700 confocal laser-scanning 
microscope (Zeiss, Germany). 
Treadscan analysis 
The Treadscan analyses were designed according to a pub-
lished protocol (Beare et al., 2009). Briefly, the device con-
sists of a motor-driven transparent belt with a mirror below, 
a high-speed digital video camera which recorded the view 
reflected from the belt by the mirror, and a transparent  
17 cm×5 cm compartment above the belt which ensured that 
the mouse stayed in place. Treadscan software (CleverSys) 
recognized each paw image of the mouse in order to analyze 
the walking pattern. All groups of mice were trained for two 
weeks from one week before immunization to one week 
after immunization, and each week contained four sessions. 
In a training session, mice were trained to walk on the mo-
tor-driven belt at a constant speed of 20 cm s1 for 1 min. 
Because sick (or EAE induced) mice were unable to reach a 
speed of 20 cm s1, a lower speed of 5 cm s1 was set for 
them. Mice that received two weeks training were recorded 
by video two months post immunization. Each mouse had 
three videos taken and they ran on the belt for 30 s per vid-
eo. Videos in which the animals ran continuously without 
stopping were used for analysis. The outlines of paws were 
deleted to make sure the data reflected the normal walking 
patterns of the mice. Four indexes—instant speed, swing 
time, stride time, and stride length—were collected. 
Open-field test 
The open-field test is an experiment to evaluate general 
locomotor activity levels and anxiety in rodents (Crusio, 
2001). At the beginning of the test, the arena was cleaned to 
remove any residual scent from other mice. All groups of 
mice were tested one month after immunization. Each 
mouse was placed in the center of the square arena. A 
high-speed digital camera was fixed on top of the arena to 
record the movement of the mice in the arena for five min. 
Videos were analyzed by Topscan software. A central area 
was defined in the floor of the arena, consisting of a con-
centric square that covered 1/4 of the floor area. Three in-
dexes—total running distance, entries into the central area, 
and average speed—were used to reflect the motor function 
of the mice. 
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